Pulmonary hypertension in chronic interstitial lung disease: a French nationwide study

Background Pulmonary hypertension (PH) associated with lung disease (Group 3 PH), including interstitial lung disease-associated PH (ILD-PH), is a severe condition with high clinical burden and mortality. However, its epidemiology and real-world burden in France remain insufficiently characterised. Method Using the French National Health Data System (SNDS), this retrospective study identified Group 3 PH and ILD-PH cases between 2017 and 2019 through a published algorithm. For incident ILD-PH patients, incidence, prevalence, survival, treatment patterns, healthcare resource utilisation (HCRU) and costs were assessed through 2022. Results Among 2615 Group 3 PH patients, of whom 1119 had ILD-PH, 759 incident ILD-PH cases were identified, including 551 who underwent right heart catheterisation (RHC). Average annual incidence of ILD-PH was 4.97 per million per year (95% CI 4.36–5.59) and prevalence was 7.35 per million (95% CI 6.60–8.09). 3-year overall survival was 52% (95% CI 48.5–55.8). Nearly half (48%) and 63% received PH- and chronic lung disease-specific treatments, respectively. HCRU included 2.61 inpatient hospitalisations (95% CI 2.54–2.68) and 16.77 general practitioner visits (95% CI 16.59–16.95) per patient-year (PPY). Annual costs reached EUR 12 908.43 for hospitalisations (95% CI EUR 12 903.46–12 913.40) and EUR 10 540.44 for primary care (95% CI EUR 10 535.95–10 544.94) PPY. PH-specific treatments represented the largest share of drug expenditures. Conclusion ILD-PH in France is rare but severe, with significant medical and economic burden. Frequent RHC use reflects adherence to guideline-recommended diagnostic pathways. These findings inform healthcare planning, acknowledging claims-based data limitations.

Authors

Publication Details

Journal
ERJ Open Research
Published
2026-11-19
DOI
https://doi.org/10.1183/23120541.00633-2026
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pulmonary hypertension in chronic interstitial lung disease: a French nationwide study

Aurélie Chekroun Martinot, Vincent Cottin, Batourou Sano, N. Petrica et al.
ERJ Open Research
Pulmonary Hypertension Research and Treatments
article

Pulmonary hypertension in chronic interstitial lung disease: a French nationwide study

Aurélie Chekroun Martinot, Vincent Cottin, Batourou Sano, N. Petrica, Míriam Fernández Delgado, Diego Funes, Olivier Sitbon
article en

Abstract

Background Pulmonary hypertension (PH) associated with lung disease (Group 3 PH), including interstitial lung disease-associated PH (ILD-PH), is a severe condition with high clinical burden and mortality. However, its epidemiology and real-world burden in France remain insufficiently characterised. Method Using the French National Health Data System (SNDS), this retrospective study identified Group 3 PH and ILD-PH cases between 2017 and 2019 through a published algorithm. For incident ILD-PH patients, incidence, prevalence, survival, treatment patterns, healthcare resource utilisation (HCRU) and costs were assessed through 2022. Results Among 2615 Group 3 PH patients, of whom 1119 had ILD-PH, 759 incident ILD-PH cases were identified, including 551 who underwent right heart catheterisation (RHC). Average annual incidence of ILD-PH was 4.97 per million per year (95% CI 4.36–5.59) and prevalence was 7.35 per million (95% CI 6.60–8.09). 3-year overall survival was 52% (95% CI 48.5–55.8). Nearly half (48%) and 63% received PH- and chronic lung disease-specific treatments, respectively. HCRU included 2.61 inpatient hospitalisations (95% CI 2.54–2.68) and 16.77 general practitioner visits (95% CI 16.59–16.95) per patient-year (PPY). Annual costs reached EUR 12 908.43 for hospitalisations (95% CI EUR 12 903.46–12 913.40) and EUR 10 540.44 for primary care (95% CI EUR 10 535.95–10 544.94) PPY. PH-specific treatments represented the largest share of drug expenditures. Conclusion ILD-PH in France is rare but severe, with significant medical and economic burden. Frequent RHC use reflects adherence to guideline-recommended diagnostic pathways. These findings inform healthcare planning, acknowledging claims-based data limitations.

ERJ Open Research
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon